Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 2/6 |
Financial Health | 5/6 |
Dividends | 2/6 |
Shanghai Yizhong Pharmaceutical Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥57.24 |
52 Week High | CN¥93.00 |
52 Week Low | CN¥48.60 |
Beta | -0.93 |
1 Month Change | 3.60% |
3 Month Change | -5.37% |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -35.86% |
Recent News & Updates
Recent updates
Shareholder Returns
688091 | CN Pharmaceuticals | CN Market | |
---|---|---|---|
7D | 2.0% | 0.3% | -1.8% |
1Y | n/a | 0.2% | -5.2% |
Return vs Industry: Insufficient data to determine how 688091 performed against the CN Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 688091 performed against the CN Market.
Price Volatility
688091 volatility | |
---|---|
688091 Average Weekly Movement | 6.4% |
Pharmaceuticals Industry Average Movement | 4.6% |
Market Average Movement | 4.6% |
10% most volatile stocks in CN Market | 8.3% |
10% least volatile stocks in CN Market | 2.9% |
Stable Share Price: 688091 is more volatile than 75% of CN stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: 688091's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2009 | 243 | Jingsong Zhou | https://www.yizhongpharma.com |
Shanghai Yizhong Pharmaceutical Co., Ltd. engages in the development of anti-tumor drugs and related products in China. It develops a dosage form of paclitaxel, an anti-tumor chemotherapeutic. Shanghai Yizhong Pharmaceutical Co., Ltd.
Shanghai Yizhong Pharmaceutical Co., Ltd. Fundamentals Summary
688091 fundamental statistics | |
---|---|
Market Cap | CN¥9.06b |
Earnings (TTM) | CN¥169.31m |
Revenue (TTM) | CN¥348.83m |
53.5x
P/E Ratio26.0x
P/S RatioIs 688091 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
688091 income statement (TTM) | |
---|---|
Revenue | CN¥348.83m |
Cost of Revenue | CN¥24.09m |
Gross Profit | CN¥324.75m |
Other Expenses | CN¥155.43m |
Earnings | CN¥169.31m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 1.07 |
Gross Margin | 93.09% |
Net Profit Margin | 48.54% |
Debt/Equity Ratio | 1.4% |
How did 688091 perform over the long term?
See historical performance and comparison